Drug Trial Radar · NCT06346392
AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2
Last checked: Nov 19, 2026Latest source record: Oct 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
594
Actual
Start
Mar 4, 2024
Primary completion
May 31, 2026
Study completion Oct 14, 2026
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- First posted
- Apr 4, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 130 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to measure the efficacy and safety of AZD0901 compared to Investigator's choice of therapy as 2L+ treatment for participants with advanced or metastatic gastric or GEJ adenocarcinoma expressing CLDN18.2.
Conditions
- Gastric Cancer
- Gastroesophageal Junction Cancer
Interventions
AZD0901Drug
Participants in the AZD0901 arm 1 will receive dose level 1 AZD0901 IV
AZD0901Drug
Participants in the AZD0901 arm 2 will receive dose level 2 AZD0901 IV (Enrolment was closed)
Ramucirumab+ paclitaxelDrug
Ramucirumab 8 mg/kg IV on Days 1 and 15 and paclitaxel 80 mg/m2 IV on Days 1, 8, and 15, Q4W
PaclitaxelDrug
Paclitaxel 80 mg/m2 IV on Days 1, 8, and 15, Q4W (for participants with contraindication to ramucirumab only)
DocetaxelDrug
Docetaxel 75-100 mg/m2 IV on Day 1, Q3W (for participants with contraindication to ramucirumab only)
IrinotecanDrug
Irinotecan 150-180 mg/m2 IV on Days 1 and 15, Q4W
TAS-102Drug
TAS-102 35 mg/m2 up to a maximum of 80 mg orally twice a day on Days 1 to 5 and Days 8 to 12, Q4W (except China)
ApatinibDrug
Apatinib 500-850 mg at Investigator's discretion based on participant's condition and tolerability, orally once daily, Q4W (China only)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression Free Survival (PFS) in all randomized participantsTime frame: From date of first dose/randomisation until disease progression or death in the absence of progression (approximately 3 years).
- Overall Survival (OS) for 3L+ participantsTime frame: From date of first dose/randomisation until the date of death due to any cause (approximately 3 years).
Locations
158 sites in 19 countries. Site status is shown where the registry gives one.
Research Site
Mobile, Alabama
Research Site
Tucson, Arizona
Research Site
Duarte, California
Research Site
Irvine, California
Research Site
Los Angeles, California
Research Site
Los Angeles, California
Research Site
Newport Beach, California
Research Site
Washington D.C., District of Columbia
Research Site
Hollywood, Florida
Research Site
Orlando, Florida
Research Site
Marietta, Georgia
Research Site
Boise, Idaho
Research Site
Lexington, Kentucky
Research Site
Boston, Massachusetts
Research Site
Ann Arbor, Michigan
Research Site
Ann Arbor, Michigan
Research Site
Kansas City, Missouri
Research Site
Mineola, New York
Research Site
New York, New York
Research Site
New York, New York
Research Site
New York, New York
Research Site
Philadelphia, Pennsylvania
Research Site
York, Pennsylvania
Research Site
Charlottesville, Virginia
Research Site
Fredericksburg, Virginia
Research Site
Olympia, Washington
Research Site
Ribeirão Preto, Brazil
Research Site
São Paulo, Brazil
Research Site
Vitória, Brazil
Research Site
Barrie, Ontario, Canada
Research Site
London, Ontario, Canada
Research Site
North York, Ontario, Canada
Research Site
Ottawa, Ontario, Canada
Research Site
Toronto, Ontario, Canada
Research Site
Montreal, Quebec, Canada
Research Site
Beijing, China
Research Site
Changchun, China
Research Site
Chengdu, China
Research Site
Chengdu, China
Research Site
Fuzhou, China
Showing 40 of 158 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.